ArticleCancers2026
Durable Progression-Free and Treatment-Free Survival After Nivolumab Plus Ipilimumab Therapy in Metastatic Renal Cell Carcinoma: A Real-World Study with a 5-Year Minimum Follow-Up.
Article in Cancers, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND/
objectivesNivolumab plus ipilimumab (IO-IO) provides durable clinical benefit in metastatic renal cell carcinoma (mRCC), yet long-term real-world data focusing on progression-free and treatment-free (PF-TF) survival remain limited. This study aimed to evaluate the long-term outcomes of IO-IO with a particular focus on the frequency and clinical characteristics of PF-TF.
methodsWe retrospectively analyzed 63 patients with mRCC treated with first-line IO-IO across eight institutions with a minimum potential follow-up of five years. Progression-free survival (PFS), PFS2, and overall survival (OS) were assessed. PF-TF was defined as absence of disease progression and any cancer-directed therapy at the five-year landmark. Clinical and treatment-related factors were compared between patients with and without PF-TF.
resultsThe median PFS, PFS2, and OS were 7.5 (95% confidence interval [CI], 5.1-13.3), 26.2 (95% CI, 13.6-46.6), and 47.4 months (95% CI, 29.3-not reached), respectively. At 5 years, 11 patients (17%) achieved PF-TF. Baseline characteristics, IMDC risk classification, and peripheral blood biomarkers were not predictive of PF-TF. PF-TF was associated with the absence of bone metastases, presence of lymph node metastases, and occurrence of immune-related adverse events (irAEs), as well as the delayed onset of irAEs. No PF-TF patients required corticosteroid pulse therapy, and durable PF-TF was observed even after early treatment discontinuation due to adverse events.
conclusionsIO-IO demonstrated sustained long-term efficacy in real-world practice, with a subset achieving durable PF-TF. These findings highlight IO-IO as a strategy capable of providing long-term disease control with reduced treatment burden in selected patients with mRCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.